Integral DiagnosticsITGDF 73 PS Ratio is 1.92 as of Jul. 01, 2026, which is 11% above its 10-year median of 1.73. GuruFocus rates ITGDF with a GF Score™ of 73/100 and a GF Value™ of $1.39. The stock has 9 warning signs investors should review. Among 200 Medical Diagnostics & Research companies, Integral Diagnostics ranks better than 83% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Integral Diagnostics's share price is $2.6125.
Integral Diagnostics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $1.36. Hence, Integral Diagnostics's PS Ratio for today is 1.92.
Good Sign:
Integral Diagnostics Ltd stock PS Ratio (=0.98) is close to 10-year low of 0.92.
The historical rank and industry rank for Integral Diagnostics's PS Ratio or its related term are showing as below:
ITGDF'
s PS Ratio Range Over the Past 10 Years
Min: 0.92 Med: 1.73 Max: 3.6
Current: 2.51
During the past 10 years, Integral Diagnostics's highest PS Ratio was 3.60. The lowest was 0.92. And the median was 1.73.
ITGDF's PS Ratio is ranked better than 83% of 200
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.815
vs ITGDF: 2.51
Integral Diagnostics Ltd revenue growth has slowed down over the past 12 months.
During the past 12 months, the average Revenue per Share Growth Rate of Integral Diagnostics was 1.60% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 6.50% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 6.80% per year.
During the past 10 years, Integral Diagnostics's highest 3-Year average Revenue per Share Growth Rate was 11.10% per year. The lowest was 5.40% per year. And the median was 6.90% per year.
Back to Basics: PS Ratio
Integral Diagnostics (OTCPK:ITGDF) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Integral Diagnostics PS Ratio Related Terms
Integral Diagnostics PS Ratio Historical Data
* Premium members only.
The historical data trend for Integral Diagnostics's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Integral Diagnostics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Integral Diagnostics PS Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Integral Diagnostics's PS Ratio distribution charts can be found below:
* The bar in red indicates where Integral Diagnostics's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Integral Diagnostics's Share Price of today is $2.6125.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Integral Diagnostics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $1.36.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Integral Diagnostics (ITGDF) has a PS Ratio of 1.92 as of Jul. 01, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Integral Diagnostics and its competitors. This is 11% above median its historical median of 1.73. Over the past decade, Integral Diagnostics' PS Ratio has ranged from 0.92 to 3.60. According to the industry distribution chart, Integral Diagnostics ranks #34 out of 200 companies in the Medical Diagnostics & Research industry, placing it in the top 17%.
Is Integral Diagnostics' PS Ratio too high?
Integral Diagnostics' current PS Ratio of 1.92 is 11% above median its 10-year median of 1.73. Over the past 10 years, this metric has ranged from a low of 0.92 to a high of 3.60. The Medical Diagnostics & Research industry median PS Ratio is 2.82. Integral Diagnostics' value of 1.92 is 31.8% below this industry median. Based on the distribution chart, Integral Diagnostics ranks #34 out of 200 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Integral Diagnostics has a GF Score™ of 73/100, reflecting its overall financial health beyond just this single metric.
How does Integral Diagnostics' PS Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Integral Diagnostics ranks #34 out of 200 companies for PS Ratio. This places Integral Diagnostics in the top 17% of its industry — outperforming the majority of peers. The industry median PS Ratio is 2.82. Integral Diagnostics' value of 1.92 is 31.8% below this benchmark. Historically, Integral Diagnostics' own PS Ratio has ranged from 0.92 to 3.60 over the past decade. While the company's 10-year median is 1.73 vs. the industry median of 2.82, Integral Diagnostics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Medical Diagnostics & Research company?
The median PS Ratio among Medical Diagnostics & Research companies is 2.82, based on 200 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Integral Diagnostics's current PS Ratio of 1.92 is 31.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Integral Diagnostics and its competitors. For the Medical Diagnostics & Research industry, the median PS Ratio is 2.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Integral Diagnostics's current PS Ratio is 1.92, which is 11% above median its own 10-year median of 1.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Integral Diagnostics stock overvalued right now?
Integral Diagnostics (ITGDF) has a current PS Ratio of 1.92. The stock's GF Value™ is $1.39, compared to a current price of $2.61 — trading 87.9% above its estimated fair value. The current PS Ratio is 1.92, which is 11% above median its 10-year median of 1.73 and 31.8% below the Medical Diagnostics & Research industry median of 2.82. Integral Diagnostics' overall GF Score™ is 73/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Integral Diagnostics (ITGDF), the current PS Ratio is 1.92 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Integral Diagnostics (ITGDF) Overvalued in 2026?
Based on GuruFocus' analysis, Integral Diagnostics stock appears to be overvalued.
The current stock price of $2.61 is trading 87.9% above its estimated GF Value™ of $1.39.
Key valuation signals for ITGDF:
PS Ratio: 1.92 (11% above median its 10-year median of 1.73)
GF Value™: $1.39 vs. price of $2.61 (87.9% above fair value)
Industry Position: 31.8% below the Medical Diagnostics & Research median (#34 of 200)
No single metric tells the full story. See the ITGDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Integral Diagnostics is a major Australian diagnostic imaging provider. In Australia, imaging revenues are almost entirely earned via the public health Medicare system. Integral typically earns approximately 90% of group revenue from diagnostic imaging in Australia and the remainder from diagnostic imaging in Auckland, New Zealand. In Australia, Integral services regional areas in Queensland, Victoria, New South Wales, and Western Australia.
73GF Score
Get the complete analysis for ITGDF
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ITGDF has been successfully added to your 
